12:00 AM
 | 
Jan 21, 2008
 |  BioCentury  |  Emerging Company Profile

Predictive Bio: Putting cancer in silos

A non-invasive diagnostic that could determine the presence or absence of cancer would significantly reduce the number of patients who unnecessarily go through colonoscopies, cystoscopies and biopsies only to discover they are disease free. Predictive Biosciences Inc. is developing urine-based assays that could enable physicians to diagnose new cancers and monitor cancer survivors with significantly less cost, time and inconvenience than current options.

"Billions of healthcare dollars are used to screen patients who might be at risk for cancer; however, only a small percentage of the patients susceptible to have cancer will actually have it," CTO Anthony Shuber told BioCentury. As an example, he said about 80% of abnormal mammograms are false positives. Finding that out currently requires needle or surgical biopsy.

Predictive also hopes its assays will allow physicians to focus more aggressive methods on high-risk patients. The company's initial focus is on survivors of epithelial cancers, including bladder, breast and colorectal cancers, who require ongoing...

Read the full 768 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >